Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.58 +8.6% TUNG 1.72 +1.8% LGO 1.03 −1.0% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.31 −1.9% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.93 −0.6% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.58 +8.6% TUNG 1.72 +1.8% LGO 1.03 −1.0% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.31 −1.9% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.93 −0.6%
Earnings Routine +

Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) 4Q26

Stonegate updates coverage on Burcon Nutrascience Corporation (BU) 4Q26

By The Northwire Desk — AI Analysis Jun 26, 2026 · 16:21 BU · 1.95 BURCON NUTRASCIENCE CORPORATION J
Executive Summary
  • Stonegate Capital Partners updates coverage on Burcon's FY26 4Q results and early FY27 commercial traction.
  • Commercial production officially launched across core protein lines (Peazazz, Puratein C, and FavaPro) in FY26.
  • 4Q26 revenue reached $0.83M CAD, up from $0.74M in 3Q26.
  • Current-quarter sales are tracking toward approximately 50% sequential growth based on April/May activity.
  • Daily production output set a new record, running roughly 60% above January-March levels.
  • Customer traction has broadened to 30+ purchasing customers and 200+ active projects across pea, canola, and fava applications.
  • Margin expansion is expected to stem from improved facility utilization, a steadier production cadence, and the removal of start-up costs from the run-rate cost structure.
  • Funding status stands at $6.9M completed and $3.0M undrawn, with management targeting $10M in CY26 sales.
  • The company is moving into a utilization ramp mode to achieve better fixed-cost absorption at the Galesburg site.
Material Impact
  • The news is a routine commercial update confirming the $10M CY26 sales target and highlighting sequential sales growth and production records.
  • It does not contain genuinely new market-relevant information that would re-rate the business. The operational progress was already telegraphed in prior updates (e.g., 50% QoQ sales growth, production records).
  • The stock's -16.6% drop into the FY26 earnings print suggests the market was focused on the $14.3M net loss and negative working capital. This update does not materially alter that negative financial narrative.
BU · Price
Company Overview
  • Burcon Nutrascience is a plant protein technology company that commercialized its Galesburg, Illinois production facility in FY26.
  • Core products include Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein.
  • The company is transitioning from technology development to commercial execution, leveraging a manufacturing partnership with RE ProMan LLC.
  • Target markets include ready-to-mix beverages, nutrition bars, snacks, baked goods, and plant-based foods.
Read the original news release →

More from BURCON NUTRASCIENCE CORPORATION J

Jun 24, 2026 · 16:12

494% revenue jump overshadowed by $14.3M loss, negative equity, and costly insider debt; liquidity a red flag.

Earnings Jun 19, 2026 · 08:01

Burcon Announces Fiscal Year 2026 Conference Call and Presentation to be Held on June 24, 2026

Earnings Jun 16, 2026 · 08:01

Commercial scaling accelerates, but negative equity and explicit capital calls keep the risk/reward skewed to the downside.

Production / Operations Apr 29, 2026 · 17:22

Burcon Announces Appointment of New Director

Management Apr 27, 2026 · 07:58

Burcon Closes Final Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million

Financings Apr 20, 2026 · 08:01

Burcon NutraScience Ramps Production Amidst Cash Burn Concerns

Production / Operations